Nailing the LacY mechanism

Credit: © 2003 AAAS" /> Credit: © 2003 AAAS Researchers including H. Ronald Kaback of the University of California, Los Angeles, had been attempting for more than a decade to crystallize LacY, the lactose permease of Escherichia coli. ?After hitting my head against the wall with the wild type, it occurred to me that it might be a good idea to try the mutant,? Kaback writes in an E-mail. In the early 1980s Kaback had stumbled upon a thermostable, nonaggregatin

Written byIshani Ganguli
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Researchers including H. Ronald Kaback of the University of California, Los Angeles, had been attempting for more than a decade to crystallize LacY, the lactose permease of Escherichia coli. ?After hitting my head against the wall with the wild type, it occurred to me that it might be a good idea to try the mutant,? Kaback writes in an E-mail.

In the early 1980s Kaback had stumbled upon a thermostable, nonaggregating mutant form of the protein trapped in its cytoplasm-facing conformation during an attempt to make a functional cysteine-free protein. He sent the sample to So Iwata at Imperial College London, who succeeded in growing the crystals. In 2003, the teams? 3.5 angstrom structure substantiated previous hints of its ?alternating access? cotransport mechanism.1 In this model, a single binding site in LacY opens outward to bind lactose and H+ and then opens inward to release them, thereby powering the movement ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies